期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新型多巴胺受体激动剂与帕金森病 被引量：11

New-generation dopamine agonists and Parkinson＇s disease
原文传递
导出
摘要 帕金森病（Parkinson’s disease，PD）是一种常见的锥体外系疾病，临床表现以震颤、肌肉僵硬为主，伴有植物神经功能、认知和情感功能障碍等非运动症状。其病理改变为中脑黑质的多巴胺（dopamine，DA）能神经元缓慢进行性变性和死亡，导致黑质、纹状体DA转运体、DA显著减少，最终导致锥体外系功能失调，从而出现上述行为障碍。
作者 姚亚妮 杨新玲
机构地区 新疆医科大学第一附属医院神经医学中心
出处 《中华神经医学杂志》 CAS CSCD 北大核心 2009年第5期538-540,共3页 Chinese Journal of Neuromedicine
基金 新疆医科大学第一附属医院循证医学专项基金（20071108-2）
关键词 新型多巴胺受体激动剂 帕金森病 New-generation dopamine agonists Parkinson＇ s disease
分类号 R686 [医药卫生—骨科学]
  • 相关文献

参考文献22

  • 1Sawamoto N, Picconi P, Hotton G, et al. Cognitive deficits and striato-front aldopamine release in Parkinson' s disease [J]. Brain, 2008, 131(Pt5): 1294-1302.
  • 2Zhang ZX, Anderson DW, Huang JB, et al. Prevalence of Parkinson's disease and related disorders in the elderly population of greater Beijing, China[J]. Mov Disord, 2003, 18 (7): 764-772.
  • 3Le Witt PA, Nyholm D. New development in Levodapa therapy[J]. Neurology, 2004, 62(1): 9.
  • 4Jankovic J. Levodopa strengths and weaknesses [J]. Neurology, 2002, 58(4 suppl 1): S19-32.
  • 5Lebrun-Frenay C, Borg M. Choosing the right dopamine agonist for patients with Parkinson ' s disease[J]. Curr Med Res Opin, 2002, 18(4): 209-214.
  • 6王新德.左旋多巴治疗帕金森病的回顾和展望[J].中华老年医学杂志,2004,23(2):129-131. 被引量：13
  • 7Clarke CE, Guttman M. Levodopa agonist monotherapy in Parkinson' s disease[J]. Lancet, 2002, 360(9347): 1767-1769.
  • 8Hershey T, Black KJ, Carl JL, et al. Long term treatment and disease severity change brain responses to levodopa in Parkinson' s disease[J]. J Neurol Neurosurg Psychiatry, 2003, 74(7): 844-851.
  • 9Tan EK, Jankovic J. Choosing dopamine agonists in Parkinson's disease[J]. Clin Neuropharmacol, 2001, 24(5): 247-253.
  • 10Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson' s disease[J]. Neurology, 2002, 58(Suppl 1): S1-8.

二级参考文献9

  • 1Mizuno Y,Yanagisawa N,Kuno S,et al.Randomized,doubleblind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease.Mov Disord,2003,18:1149-1156.
  • 2Pinter MM,Rutgers AW,Hebenstreit E,et al.An open-label,multicentre clinical trial to determine the levodopa dose-sparing capacity of Pramipexole in patients with idiopathic Parkinson's disease.J Neural Transm,2000,107:1307-1323.
  • 3Reichmann H,Brecht MH,Koster J,et al.Pramipexole in routine clinical practice:a prospective observational trial in Parkinson's disease.CNS Drugs,2003,17:965-973.
  • 4Holloway RG,Shoulson I,Fahn S,et al.Pramipexole vs levodopa as initial treatment for Parkinson's disease:a 4-year randomized controlled trial.Arch Neurol,2004,61:1044-1053.
  • 5Linazasoro G,Spanish Dopamine Agonists Study Group.Conversion from dopamine agoists to Pramipexole.An open-label trial in 227 patients with advanced Parkinson's disease.J Neurol,2004,251:335-339.
  • 6Gu M,Iravani MM,Cooper JM,et al.Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms.J Neurochem,2004,91:1075-1081.
  • 7Asanuma M,Miyazaki I,Diaz-Corrales FJ,et al.Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopaminesemiquinone generated in vitro.Neurol Res,2005,27:533-539.
  • 8Moller JC,Oertel WH,Koster J,et al.Long-term efficacy and safety of pramipexole in advanced Parkinson's disease:results from a European multicenter trial.Mov Disord,2005,20:602-610.
  • 9Mierau J,Schingnitz G.Biochemical and Pharmacological studies on Pramipxole,a potent and selective D2 receptor agonist.Eur J Pharmacol,1992,215:161-170.

共引文献74

同被引文献164

引证文献11

二级引证文献111

中华神经医学杂志
2009年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部